Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04953143 · ClinicalTrials.gov registry record · NA
LiverPAL: A Pilot Study of Inpatient Palliative Care for Patients With Advanced Liver Disease
A NA study of Cirrhosis, Liver, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT04953143 is a NA study of Cirrhosis, Liver that has completed, run by Massachusetts General Hospital. The registered enrollment target is 25 participants, below the 241-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04953143, a NA study of Cirrhosis, Liver, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Frequently patients with advanced liver disease experience physical and emotional symptoms during their hospitalization that can may cause a level of discomfort to both the patient and the family members that surround them. This study involves the early introduction of a team of clinicians that specialize in the lessening (palliation) of many of these discomforting symptoms. This team of clinicians is called the palliative care team and they focus on ways to improve pain and other symptom management and to assist patients and their families in coping with the physical, emotional and social issues associated with a diagnosis of advanced liver disease. The team consists of physicians and advance practice nurses who have been specially trained in the care of patients facing serious illness and their caregivers. The investigators are studying the feasibility of delivering this program, the acceptability and satisfaction with the program, and changes in the quality of life, illness understanding, and symptoms of hospitalized patients who receive the program and their caregivers. The study will use a series of questionnaires to measure the study participants' quality of life, physical symptoms, illness and prognostic understanding, and mood. Study questionnaires will be completed in the hospital, home or clinic. Qualitative interviews will be conducted with hepatology and palliative care clinicians as well as patients and caregivers.
Conditions Studied
Interventions
- BEHAVIORAL LiverPal Intervention
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-01-14 |
| Est. Completion | 2022-08-16 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04953143
The ClinicalTrials.gov registry entry for NCT04953143 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 241-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (90% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cirrhosis, Liver appearing as the primary indexed condition, and to 1 intervention - of which LiverPal Intervention is the first listed.
NCT04953143 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04953143 about?
NCT04953143 is a clinical study titled "LiverPAL: A Pilot Study of Inpatient Palliative Care for Patients With Advanced Liver Disease". Frequently patients with advanced liver disease experience physical and emotional symptoms during their hospitalization that can may cause a level of discomfort to both the patient and the family members that surround them. This study involves the early introduction of a team of clinicians that spe...
What is the current status of trial NCT04953143?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2022-01-14. Estimated completion is 2022-08-16.
What conditions does trial NCT04953143 study?
This clinical trial studies the following conditions: Cirrhosis, Liver.
What interventions are being tested in trial NCT04953143?
The interventions under investigation include: LiverPal Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT04953143?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04953143 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis, Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Molecular Mechanism of Exercise in Cirrhosis
RECRUITING · NA
-
HMB Enriched Amino Acids to Reverse Muscle Loss in Cirrhosis
RECRUITING · NA
-
Initial Resuscitation for Acute Kidney Injury in Cirrhosis
RECRUITING · NA
-
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
RECRUITING · NA
-
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
RECRUITING · NA
-
Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.